Glioma–Astrocyte Connexin43 Confers Temozolomide Resistance Through Activation of the E2F1/ERCC1 Axis

Medicine, Neurology, Pharmacy, Oncology,
glioma   temozolomide resistance   Connexin43   E2F1/ERCC1 axis   tumor microenvironment   astrocytes   chemoresistance  

Study on Connexin43-Mediated Temozolomide Resistance in Glioma through Activation of the E2F1/ERCC1 Axis Academic Background Glioma is the most common and fatal tumor of the central nervous system, with temozolomide (TMZ) being the standard treatment. However, TMZ therapy often leads to tumor recurrence and drug resistance, severely limiting its ef...

The Novel DNA Cross-Linking Agent KL-50 is Active Against Patient-Derived Models of New and Recurrent Post-Temozolomide Mismatch Repair-Deficient Glioblastoma

Medicine, Neurology, Oncology,
glioblastoma   DNA cross-linking agent   mismatch repair deficiency   temozolomide   KL-50   patient-derived xenograft models   novel therapy  

Breakthrough Study on KL-50 in Treating Recurrent Glioblastoma Background Glioblastoma (GBM) is a highly malignant brain tumor, particularly in patients with IDH wild-type (IDHwt), who have a very poor prognosis. Although the current standard treatment includes surgical resection, radiotherapy, and Temozolomide (TMZ) chemotherapy, most patients eve...

TRIM21-Mediated Ubiquitination and Phosphorylation of ERK1/2 Promotes Cell Proliferation and Drug Resistance in Pituitary Adenomas

Medicine, Endocrinology, Neurology, Neurosurgery, Oncology,
TRIM21   ERK1/2   pituitary adenomas   cell proliferation   drug resistance   ubiquitination   phosphorylation  

Academic Background Pituitary adenomas (PAs) are common intracranial tumors with complex pathogenesis, often accompanied by abnormal hormone secretion. Although various treatments, such as dopamine agonists (DAs), are currently available, some patients exhibit drug resistance, leading to suboptimal therapeutic outcomes. Therefore, identifying new t...

The Prognostic Impact of CDKN2A/B Hemizygous Deletions in IDH-Mutant Glioma

Medicine, Neurology, Oncology,
glioma   IDH mutation   CDKN2A/B deletion   prognosis   neuro-oncology  

Background Introduction Glioma is one of the most common primary tumors of the central nervous system, and its prognosis and treatment methods vary significantly depending on molecular characteristics. In recent years, with the advancement of molecular pathology, IDH (isocitrate dehydrogenase) mutations have been identified as important molecular m...

Reappraisal of Prognostic Factors in CNS WHO Grade 3 Oligodendrogliomas IDH-Mutant and 1p/19q Co-Deleted: Lessons from the French POLA Cohort

Medicine, Neurology, Oncology,
oligodendroglioma   prognostic factors   IDH mutation   1p/19q co-deletion   French POLA cohort   pathological groups   contrast enhancement  

Reappraisal of Prognostic Factors in CNS WHO Grade 3 Oligodendrogliomas: Insights from the French POLA Cohort Academic Background Oligodendroglioma is a relatively rare primary brain tumor in the central nervous system (CNS), characterized by IDH gene mutations and 1p/19q co-deletion. According to the World Health Organization (WHO) classification ...

Clinical and Genetic Markers of Vascular Toxicity in Glioblastoma Patients: Insights from NRG Oncology RTOG-0825

Medicine, Neurology, Oncology, Life Sciences, Genetics,
Glioblastoma   Vascular Toxicity   Genetic Markers   Hypertension   Thrombosis   Clinical Prediction Model   Genome-Wide Association Study  

Clinical and Genetic Markers of Vascular Toxicity in Glioblastoma Patients: Insights from NRG Oncology RTOG-0825 Academic Background Glioblastoma (GBM) is a highly aggressive form of brain cancer, accounting for nearly 80% of malignant primary brain tumors. Despite standard treatments including surgical resection, radiotherapy, and chemotherapy, th...

Development of an Orthotopic Medulloblastoma Zebrafish Model for Rapid Drug Testing

Medicine, Pediatrics, Neurology, Oncology,
medulloblastoma   zebrafish model   drug testing   neural stem cells   tumor growth  

Academic Background Medulloblastoma (MB) is one of the most common malignant brain tumors in children. Although recent advances in molecular characterization and multimodal treatment have significantly improved patient survival rates, the prognosis of medulloblastoma remains closely related to molecular subtypes, particularly for patients with Grou...

Efficacy of 3D-TSE Sequence-Based Radiosurgery in Prolonging Time to Distant Intracranial Failure: A Session-Wise Analysis in a Histology-Diverse Patient Cohort

Medicine, Neurology, Medical Imaging, Oncology,
Radiosurgery   3D-TSE sequence   Distant Intracranial Failure   Brain Metastases   Imaging Protocol  

Efficacy of 3D-TSE Sequence in Prolonging Time to Distant Intracranial Failure: A Session-Wise Analysis in a Histology-Diverse Patient Cohort Academic Background Brain metastases (BM) represent the majority of intracranial malignancies and significantly contribute to cancer-related morbidity and mortality. At the initial diagnosis of systemic cance...

Alternative Lengthening of Telomere-Based Immortalization Renders H3G34R-Mutant Diffuse Hemispheric Glioma Hypersensitive to PARP Inhibitor Combination Regimens

Medicine, Neurology, Oncology,
alternative lengthening of telomeres   H3G34R mutation   diffuse hemispheric glioma   PARP inhibitors   DNA damage stress  

Background Introduction Diffuse Hemispheric Glioma (DHG) is a highly aggressive and poorly prognostic high-grade glioma, particularly prevalent in children and adolescents. The H3G34R/V mutation is one of the common genetic alterations in this type of tumor, often accompanied by the inactivation of the ATRX (Alpha-Thalassemia/Mental Retardation Syn...

Phase II Trial of Pathology-Based Tripartite Treatment Stratification for Patients with CNS Germ Cell Tumors: A Long-Term Follow-Up Study

Medicine, Neurology, Neurosurgery, Oncology,
CNS germ cell tumors   long-term follow-up   tripartite treatment   pathology   survival rates   relapse   complications  

Long-Term Follow-Up Study of Central Nervous System Germ Cell Tumors: Pathology-Based Tripartite Treatment Stratification Academic Background Central nervous system germ cell tumors (CNS GCTs) are rare tumors primarily occurring in adolescents, especially males aged 12 to 16. These tumors are believed to originate from primordial germ cells (PGCs),...